Quantamental Technologies’s BioMarin Pharmaceuticals BMRN Stock Holding History

Quantamental Technologies’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-4,037	Closed	-$272K	–	531
2019 Q3	$272K	Buy	+4,037	New	+$311K	0.09%	380
2019 Q2	–	Sell	-820	Closed	-$73K	–	1479
2019 Q1	$73K	Sell	820 -728	-47%	-$67.5K	0.03%	716
2018 Q4	$132K	Buy	+1,548	New	+$147K	0.08%	460

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Quantamental Technologies's BMRN Position: Q4 2019 in Review

Quantamental Technologies sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2019, closing a stake of 4,037 shares — an estimated $272K sold.

Quantamental Technologies first reported a position in BMRN in Q4 2018 and held it in 3 quarters. The position peaked at $272K in Q3 2019. 467 funds tracked by Wall St. Rank hold BMRN as of Q4 2019.

Quantamental Technologies reported no remaining BioMarin Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Quantamental Technologies sold 4,037 BioMarin Pharmaceuticals shares in Q4 2019, an estimated $272K.
Quantamental Technologies first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 3 quarters.
Quantamental Technologies's BioMarin Pharmaceuticals position peaked at $272K in Q3 2019.
467 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2019.

Based on Quantamental Technologies's 13F filing for Q4 2019, filed 14 Feb 2020.